Balancing Efficacy and Safety: Modulating the Immune System with SUPRA CAR-T Cells for Cancer Therapy

Junming Chen

doi:10.47297/wspbdsWSP2752-630520.20250501

PDF
Export
Share
Collection
Album

Balancing Efficacy and Safety: Modulating the Immune System with SUPRA CAR-T Cells for Cancer Therapy

Volume 5, Issue 1

Views: 0 Downloads: 0

Balancing Efficacy and Safety: Modulating the Immune System with SUPRA CAR-T Cells for Cancer Therapy
Balancing Efficacy and Safety: Modulating the Immune System with SUPRA CAR-T Cells for Cancer Therapy
University of Bristol, Unite Kingdom, Senate House, Tyndall Avenue, Bristol, BS8 1TH, United Kingdom
Vol. 5, Issue 1, Pages: 88-92(2025)
Published：19 March 2025
DOI：10.47297/wspbdsWSP2752-630520.20250501
Accepted：

Scan QR Code

Chen Junming.Balancing Efficacy and Safety: Modulating the Immune System with SUPRA CAR-T Cells for Cancer Therapy[J].Biomedical Data Science,2025,05(01):88-92.
DOI：

Chen Junming.Balancing Efficacy and Safety: Modulating the Immune System with SUPRA CAR-T Cells for Cancer Therapy[J].Biomedical Data Science,2025,05(01):88-92. DOI： 10.47297/wspbdsWSP2752-630520.20250501.

摘要

Abstract

Cancer poses considerable challenges for effective treatment

notwithstanding the existence of various therapeutic options. Immunotherapy is a strategy that employs the immune system to detect and eradicate cancer cells. This entails the identification of specific antigens on cancer cells and the direction of T cells to recognize and eliminate them. Immunotherapy produces fewer side effects than traditional treatments such as chemotherapy. Nonetheless

it presents inherent safety risks

particularly the possibility of unintentional damage to healthy cells. In response to these concerns

developed SUPRA CAR as an advanced version of the original therapy

offering improved safety and efficacy. As an emerging technology

it possesses limitations that necessitate further examination.

关键词

Keywords

references

Velilla P.A. , Rugeles M . T. and Chougnet C .A. ( 2006 ). Defective antigen-presenting cell function in human neonates. Clinical Immunology , 121 ( 3 ), pp. 251 – 259 .

Onoi K. , Chihara Y. , Uchino J. , Shimamoto T. , Morimoto Y. , Iwasaku M. , Kaneko Y. , Yamada T. and Takayama K . ( 2020 ). Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review . Journal of Clinical Medicine , 9 ( 5 ), p. 1362 .

Anichini A. , Perotti V.E. , Sgambelluri F . and Mortarini, R . ( 2020 ). Immune Escape Mechanisms in Non Small Cell Lung Cancer. Cancers , 12 ( 12 ), p. 3605 .

Anwar M.Y. , Williams G . R. and Paluri R .K. ( 2020 ). CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data. Journal of Gastrointestinal Cancer .

Schubert , M.-L. ., Schmitt M. , Wang L. , Ramos C.A. , Jordan K. , Müller-Tidow C . and Dreger, P . ( 2021 ). Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Annals of Oncology , 32 ( 1 ), pp. 34 – 48 .

Cho J.H. , Okuma A. , Sofjan K. , Lee S. , Collins J . J . and Wong , W .W. ( 2021 ). Engineering advanced logic and distributed computing in human CAR immune cells. Nature Communications, [online ] 12 ( 1 ), p. 792 .

Feucht J. , Sun J. , Eyquem J. , Ho Y . -J. , Zhao Z. , Leibold J. , Dobrin A. , Cabriolu A. , Hamieh M . and Sadelain, M . ( 2019 ). Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nature Medicine , [online ] 25 ( 1 ), pp. 82 – 88 .

Majzner R . G. and Mackall C .L. ( 2018 ). Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discovery , 8 ( 10 ), pp. 1219 – 1226 .

Evripidis Lanitis , Poussin M. , Klattenhoff A.W. , Song D . -G., Sandaltzopoulos R., June C .H. and Powell , D .J. ( 2013 ). Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo. 1 ( 1 ), pp. 43 – 53 .

Boardman A . P. and Salles G . ( 2023 ). CAR T‐cell therapy in large B cell lymphoma. Hematological Oncology , 41 (S 1 ), pp. 112 – 118 .

Ellebrecht C.T. , Bhoj V.G. , Nace A. , Choi E.J. , Mao X. , Cho M.J. , Di Zenzo G. , Lanzavecchia A. , Seykora J.T. , Cotsarelis G. , Milone M . C . and Payne , A .S. ( 2016 ). Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science (New York, N.Y.), [online ] 353 ( 6295 ), pp. 179 – 184 .

Fesnak A.D. , June C . H. and Levine B .L. ( 2016 ). Engineered T cells: the promise and challenges of cancer immunotherapy. Nature Reviews Cancer , 16 ( 9 ), pp. 566 – 581 .

Brentjens R.J. , Davila M.L. , Riviere I. , Park J. , Wang X. , Cowell L.G. , Bartido S. , Stefanski J. , Taylor C. , Olszewska M. , Borquez-Ojeda O. , Qu J. , Wasielewska T. , He Q. , Bernal Y. , Rijo I.V. , Hedvat C. , Kobos R. , Curran K . and Steinherz, P . ( 2013 ). CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Science Translational Medicine , 5 ( 177 ), pp.177ra38–177ra38.

Jiang H. , Zhang W. , Shang P. , Zhang H. , Fu W. , Ye F. , Zeng T. , Huang H. , Zhang X. , Sun W. , Man-Yuen Sze D. , Yi Q . and Hou, J . ( 2013 ). Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Molecular Oncology , 8 ( 2 ), pp. 297 – 310 .

Cho J.H. , Collins J . J. and Wong, W.W. (2018) . Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses. Cell , [online ] 173 ( 6 ), pp. 1426 - 1438 .e11.

Liu J. , Tu X. , Zhang H. , Tong Z. , Zhu X. , Zheng Y. , Zhao P. , Liu L . and Fang, W . ( 2022 ). Advances in CAR-T cell therapy for malignant solid tumors. Journal of Zhejiang University (Medical Sciences) , 51 ( 2 ), pp. 175 – 184 .

Anand Rotte , Frigault M.J. , Ansari A. , Gliner B. , Heery C . R . and Shah , B . 2022 . Dose–response correlation for CAR-T cells: a systematic review of clinical studies. [online ] 10 ( 12 ), pp. e005678 – e005678 .

Lu , J. Jiang, G. ( 2022 ). The journey of CAR-T therapy in hematological malignancies . Molecular Cancer , 21(1) .

Hou B. , Tang Y. , Li W. , Zeng Q . and Chang, D . ( 2019 ). Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis. Disease Markers , 2019 , pp. 1 – 11 .

Chao Y. , Wei T. , Li Q. , Liu B. , Hao Y. , Chen M. , Wu Y. , Song F. , Chen Q . and Liu, Z . ( 2023 ). Metformin-containing hydrogel scaffold to augment CAR-T therapy against post-surgical solid tumors. 295 , pp. 122052 – 122052 .

Hallaj S. , Meshkini F. , Chaleshtari M.G. , Ghorbani A. , Namdar A. , Soleimanpour H . and Jadidi-niaragh, F . ( 2019 ). Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy. Cellular Immunology , 345 , p. 103963 .

Truong N . T .H., Gargett T. , Brown M. P . and Ebert L.M. ( 2021 ). Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies. Cancers, [online ] 13 ( 9 ), p. 2225 .

Menez S. , Bourbon E. , Gounot R. , Tudesq J . -J., Moya N., Houot R . and Bachy , E . 2024 . CAR T-cells in very elderly (≥80 years) lymphoma patients: a DESCAR-T analysis. Leukemia & Lymphoma, pp. 1 – 4 .

Alert me when the article has been cited

Submit

Advances in CAR-T cell therapy in HCC

Related Author

Dingyi Liu Zhejiang Chinese Medical University

Related Institution

Zhejiang Chinese Medical University

⁰